NIBR2130, also known as 6-(phenylcarbamoyl)-6-nor-LSD, is a small-molecule chemokine CXCR3 receptor antagonist which has been used in scientific research. It is a lysergamide and is a derivative of the psychedelic drug lysergic acid diethylamide (LSD).

In contrast to LSD, NIBR2130 shows profoundly reduced affinities for monoamine receptors ( = 750–>10,000nM). Instead, it was surprisingly found to act as a selective and highly potent chemokine CXCR3 receptor antagonist, with an affinity () of 54nM and an inhibitory potency () of 18 to 74nM. Unlike NIBR2130, LSD itself is completely inactive at the chemokine CXCR3 receptor. NIBR2130 can fully block the chemokine CXCR3 receptor in rodents in vivo.

Various analogues of NIBR2130 have also been studied and described, with some of them substantially more potent as chemokine CXCR3 receptor antagonists and some of them acting as highly potent histamine H3 receptor antagonists with potential applications in treatment of narcolepsy.

NIBR2130 was first described in the scientific literature by 2008.

See also Substituted lysergamide

References